Public Health Emergency - Leading a Nation Prepared
This document is a template press release, which can be adapted by state, local, tribal, and territorial health departments for their ongoing public information efforts to promote monoclonal antibody treatment for high-risk COVID-19 patients. Fields highlighted in yellow should be updated to reflect the details of your local operations.
[MONTH, DAY, YEAR]
[PUBLIC INFORMAITON OFFICER NAME/EMAIL/TELEPHONE]
[health department’s] is
[describe activity] to promote availability of
COVID-19 monoclonal antibody therapeutics. These treatments mimic your immune system’s response to SARS-CoV-2 (the infection that causes COVID-19) and are available to eligible patients 12 years and older with a high risk of progressing to severe forms of COVID-19 or being hospitalized.
High-risk patients over age 12, with mild to moderate symptoms should be referred and treated with monoclonal antibodies, within 10 days of symptom onset.
Eligible patients include those with a wide variety of risk factors, including older age, obesity, pregnancy, conditions like heart, kidney, lung, sickle cell disease, asthma. The U.S. Food and Drug Administration (FDA) includes race and ethnicity as a factor, reflecting the disproportionate impact of COVID-19 on Black, Hispanic and other communities.
COVID-19 monoclonal antibodies have been
purchased by the United States Government and are available at little-to-no cost to the patient. HHS/ASPR is working with state and territorial health departments as well as national healthcare and medical organizations and associations to get the treatments into the hands of healthcare providers quickly, with a focus on areas of the country hardest hit by the pandemic. Patients should coordinate with their respective physician or care provider before
contacting a location to receive treatment.
As the essential effort to vaccinate the public continues, monoclonal antibody treatments serve as an important tool in reducing the harms of infections that occur. For people at high-risk of developing serious illness, monoclonal antibodies can significantly reduce the risk of hospitalization and alleviate burden on hospitals in the
Home | Contact Us | Accessibility | Privacy Policies | Disclaimer | HHS Viewers & Players | HHS Plain Language
Assistant Secretary for Preparedness and Response (ASPR), 200 Independence Ave., SW, Washington, DC 20201
U.S. Department of Health and Human Services | USA.gov |
HealthCare.gov in Other Languages